Results 111 to 120 of about 6,506,258 (188)

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

open access: yes, 2020
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST ...
L. Morello   +32 more
core   +1 more source

A Real‐World Study on the Use of Recombinant Human Thrombopoietin for Managing Thrombocytopenia Following Tandem Dual‐Target CAR‐T Cell Therapy in B‐Cell Malignancies

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Objective Given that CD19 chimeric antigen receptor T (CAR‐T) cell therapy frequently induces severe thrombocytopenia and recombinant human thrombopoietin (rhTPO)′s role in managing this CAR‐T‐associated cytopenia remains not well defined, we aimed to evaluate rhTPO's safety and efficacy for treating thrombocytopenia in B‐cell malignancy ...
Jiaqi Guo   +10 more
wiley   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar   +6 more
wiley   +1 more source

Unraveling the DNA Methylome in Mantle Cell Lymphoma : New Insights into the Cellular Origin

open access: yes, 2016
Our understanding of the DNA methylome and its impact on cancer evolution and disease progression is rapidly evolving. In this issue of Cancer Cell, Queiros et al.
Mansouri, Larry,, Rosenquist, Richard,
core   +1 more source

Extranodal plasmablastic lymphoma arising in mantle cell lymphoma

open access: yes, 2007
A letter to the editor is presented in response to the article "Extranodal plasmablastic lymphoma arising in mantle cell lymphoma," in previous issue of Histopathology.
Eyers, A. A.   +9 more
core   +1 more source

Fixed‐duration glofitamab in patients with relapsed or refractory follicular lymphoma: Results from a Phase 1/2 study

open access: yesHemaSphere, Volume 10, Issue 11, November 2026.
Abstract More effective options are needed to personalize treatment for relapsed/refractory (R/R) follicular lymphoma (FL) by balancing efficacy, safety, and accessibility. We report efficacy and safety of glofitamab, a CD20xCD3 T‐cell engaging bispecific antibody, from a Phase 1/2 study in patients with R/R FL after ≥2 prior therapies.
Franck Morschhauser   +19 more
wiley   +1 more source

Nasopalatal mantle cell lymphoma: A rare case report with a literature review

open access: yesJournal of Current Research in Scientific Medicine
Mantle cell lymphoma, a rare aggressive non-Hodgkin lymphoma subtype in the nasopalatine region, an uncommon encounter by the otorhinolaryngologists, is reported.
Magesh Kuppusami   +4 more
doaj   +1 more source

Incidental CD5 Negative Mantle Cell Lymphoma in a Gastrointestinal Stromal Tumor: An Unusual Case Suspicious for a Non‐Nodal Variant

open access: yes
International Journal of Laboratory Hematology, EarlyView.
Elizabeth Tingey   +2 more
wiley   +1 more source

What Is Your Diagnosis? Blood Smear From a Mixed‐Breed Dog

open access: yes
Veterinary Clinical Pathology, EarlyView.
Laura S. Peres   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy